Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes

Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM. Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes Diabetes Obes Metab

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme

Pandey A, Moroney M, Verma S, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Petrie MC, Rönnbäck C, Domdey A, Rasmussen S, Chinnakondepalli KM, Patel S, Kosiborod MN. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme Eur J Heart Fail

Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape

Mondoh A, Crotty M, le Roux CW. Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape Expert Opin Pharmacother

Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial

Platz E, Kaplan LM, le Roux CW, Wharton S, Burger S, Hussain SA, Brueckmann M, Startseva E, Fey C, Kosiborod MN, Bozkurt B. Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial JACC Heart Fail
Chronic Kidney Disesae

Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document

Monzo L, Savarese G, Mullens W, Abdin A, Bozkurt B, Chioncel O, El Hadidi S, Gorter TM, Inciardi RM, Petrie MC, Schiattarella GG, Stolfo D, Metra M, Girerd N. Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document Eur J Heart Fail

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

Giblin, Kaplan, Somers, Le Roux, Hunter, Wu, Lalonde, Ahmad, Bethel Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes, Obesity and Metabolism

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity

Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity Endocr Rev
Insulin Resistance & Diabetes

Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease

Sedrak P, Verma R, Verma M, Connelly KA. Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease The Canadian Journal of Cardiology

Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation

Carolan A, Hynes-Ryan C, Agarwal SM, Bourke R, Cullen W, Gaughran F, Hahn MK, Krivoy A, Lally J, Leucht S, Lyne J, McCutcheon RA, Norton MJ, O'Connor K, Perry BI, Pillinger T, Shiers D, Siskind D, Thompson A, O'Shea D, Keating D, O'Donoghue B. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation Schizophrenia Bulletin

ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine

Russo S, Proto L, Neto MG, Angelini G, Pezzica S, Carli F, Previti E, Caristo ME, Bove V, Chakaroun R, Roggiani S, Tremaroli V, Le Roux CW, Bornstein SR, Gastaldelli A, Boskoski I, Mingrone G. ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine Diabetes, Obesity & Metabolism

Older posts

Newer posts

← Previous Page1 … Page4 Page5 Page6 … Page30 Next →

Search for:

Recent Posts

10th ASOI Annual Scientific Meeting 2026
9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI